No Direct Metabolic Interaction Between Methotrexate and Levothyroxine
Methotrexate does not directly affect the metabolism of levothyroxine (Synthroid), but recent evidence suggests it may lower total thyroxine (T4) levels through unclear mechanisms, potentially requiring closer monitoring of thyroid function in patients taking both medications.
Key Pharmacokinetic Considerations
Methotrexate Metabolism and Excretion
Methotrexate is primarily eliminated unchanged through renal excretion (80-90% within 24 hours), with minimal hepatic metabolism 1. The drug undergoes:
- Hepatic and intracellular metabolism to polyglutamated forms
- Small amounts convert to 7-hydroxymethotrexate
- Limited biliary excretion (≤10% of dose)
- Partial metabolism by intestinal flora after oral administration
Levothyroxine Metabolism
The FDA label for Synthroid indicates that levothyroxine has a narrow therapeutic index and many drugs can necessitate dosing adjustments 2. However, methotrexate is not specifically listed among the drugs that affect levothyroxine absorption, metabolism, or transport.
Clinical Evidence of Thyroid Effects
Recent Research Findings
A 2023 cross-sectional study of 281 rheumatoid arthritis patients found that methotrexate was associated with decreased total thyroxine (TT4) levels (OR = 0.067,95%CI: 0.008-0.588, P = 0.015) 3. Patients taking methotrexate had lower TT4 levels (TT4 < 78.38 nmol/L).
Important distinction: This represents a direct thyroid effect rather than a drug-drug interaction affecting levothyroxine metabolism. The mechanism remains unclear but may involve:
- Direct effects on thyroid hormone production
- Alterations in thyroid hormone binding proteins
- Immune-mediated effects on thyroid function
Broader Context
A 2010 review on drugs affecting thyroid function does not specifically identify methotrexate as causing thyroid dysfunction, though it acknowledges that novel drug-thyroid interactions continue to emerge 4.
Clinical Recommendations
Monitoring Strategy
For patients on both methotrexate and levothyroxine:
- Baseline thyroid function tests (TSH, free T4, total T4) before starting methotrexate
- Monitor TSH and thyroid hormones every 3-6 months initially, then as clinically indicated
- Watch for symptoms of hypothyroidism (fatigue, weight gain, cold intolerance) that may indicate need for levothyroxine dose adjustment
- Time medications appropriately: Take levothyroxine on an empty stomach, 30-60 minutes before breakfast; methotrexate timing is less critical but maintain consistency
Dosing Considerations
- If thyroid function tests show declining T4 levels after starting methotrexate, consider increasing levothyroxine dose to maintain euthyroid state
- The levothyroxine dose adjustment should be based on TSH and free T4 levels, not on the presence of methotrexate alone
- Standard methotrexate monitoring (CBC, liver function, creatinine every 3-6 months) should continue 5
Common Pitfalls to Avoid
- Don't assume drug interaction: The effect is likely on thyroid hormone production, not levothyroxine metabolism
- Don't overlook baseline thyroid status: Many patients with autoimmune conditions (like rheumatoid arthritis or psoriasis) have concurrent autoimmune thyroid disease
- Don't forget methotrexate's protein binding: Methotrexate is ~50% protein-bound and can be displaced by sulfonamides, salicylates, and phenytoin 1, but this doesn't directly affect levothyroxine
- Don't neglect folic acid supplementation: All methotrexate patients should receive folic acid 1-5 mg daily (except on methotrexate day) to reduce toxicity 6, 7, 5
Bottom Line
While methotrexate doesn't metabolically interfere with levothyroxine, it may independently lower thyroid hormone levels. Maintain standard levothyroxine administration practices (empty stomach, consistent timing) and monitor thyroid function more closely when initiating or adjusting methotrexate therapy. Adjust levothyroxine doses based on thyroid function tests, not prophylactically.